Original language | English |
---|---|
Article number | 2092328 |
Journal | OncoImmunology |
Volume | 11 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jan 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: OncoImmunology, Vol. 11, No. 1, 2092328, 01.01.2022.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - The endoplasmic reticulum chaperone BiP
T2 - a target for immunogenic cell death inducers?
AU - Kepp, Oliver
AU - Bezu, Lucillia
AU - Kroemer, Guido
N1 - Funding Information: OK receives funding by the DIM ELICIT initiative of the Ile de France and Institut National du Cancer (INCa); GK is supported by the Ligue contre le Cancer (équipes labellisées, Program “Equipe labelisée LIGUE”; no. EL2016.LNCC (VT/PLP)); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Le Cancer du Sein, Parlons-en!”; Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; INCa; Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
PY - 2022/1/1
Y1 - 2022/1/1
UR - http://www.scopus.com/inward/record.url?scp=85133044104&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2022.2092328
DO - 10.1080/2162402X.2022.2092328
M3 - Editorial
C2 - 35756845
AN - SCOPUS:85133044104
SN - 2162-4011
VL - 11
JO - OncoImmunology
JF - OncoImmunology
IS - 1
M1 - 2092328
ER -